05 June
Here is our weekly roundup on the latest research and scientific efforts against the coronavirus.
Roche
Roche has received an Emergency Use Authorisation (EUA) from the U.S. Food and Drug Administration (FDA) for the Elecsys® IL-6 test. This test helps to identify patients with covid-19 who could be at high risk of severe inflammatory response.
Read more here.
AstraZeneca
AstraZeneca are moving forward with their commitment to broad and equitable global access to the University of Oxford’s COVID-19 vaccine, alongside CEPI and Gavi and the Serum Institute of India.
Read more here.
Novavax
Novavax will be partnering with AGC Biologics to manufacture Matrix-M™ adjuvant for a covid-19 vaccine to boost the immune response and stimulate high levels of neutralizing antibodies.
Read more here.
Lilly
Eli Lilly has announced that the first patients have been dosed in a Phase-1 study of LY-CoV555, the world’s first study of potential covid-19 antibody treatment. Lilly will progress into Phase-2, proof of concept study, once the Phase-1 results confirms that the antibody can be safely administered.
Read more here.
Gilead
Gilead Sciences Inc has announced results from the Phase- 3 SIMPLIE trial of remdesivir in hospitalised patients with moderate covid-19. The results have revealed that a 5 day treatment course of remdesivir has led to greater clinical improvement as opposed to treatment with standard care alone.
Read more here.
CEPI
CEPI has announced a new partnership with The University of Queensland to accelerate the development, manufacture and distribution of a Covid-19 vaccine candidate, developed by researchers at UQ.
Read more here.
Keep up to date on the response from the chemical industry and the scientific community to the COVID-19 (coronavirus) outbreak. SCI will be covering key coronavirus research and reporting news from trusted sources so that you have the coronavirus latest.
Visit Blog